NEW YORK Sales revenue from generic oncology drugs in 2020 was US$ 23 Bn , which is expected to surge to US$ 41.5 Bn by the end of 2031. Analysts at Persistence Market Research have also predicted the market to rise at a healthy CAGR of 6% over the next ten years. Instances of cancer cases have risen exponentially across the globe. From diagnosis to treatment, all aspects of the disease are being researched extensively by numerous market players.
Read the source article at PR Newswire